Gilead, Schindler, Ericsson, Rovio: Intellectual Property

Teva Pharmaceuticals agreed to delay the introduction of generic versions of two Gilead Sciences Inc. HIV drugs until June if a judge hasn’t ruled in its favor by then in a patent case brought by Gilead.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.